Market Checkup: High Cholesterol
In this edition of The Motley Fool's Market Checkup, health-care analysts David Williamson and Max Macaluso discuss the treatment of high cholesterol. From the impact of generic versions of Pfizer's Lipitor to the most exciting experimental drugs in late-stage clinical trials, cholesterol continues to be an area of focus for pharmaceutical companies and investors.
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
The article Market Checkup: High Cholesterol originally appeared on Fool.com.
David Williamson owns shares of Pfizer and Amarin plc (ADR). Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.